FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2213790147> ?p ?o ?g. }

• W2213790147 abstract "Abstract Introduction Children with acute lymphoblastic leukemia (ALL) are at high risk for VTE due to several thrombotic risk factors such as the disease itself, central venous line (CVL), immobilization, infections and treatment with asparaginase and steroids, leading to increased morbidity and mortality. Identifying the clinical risk factors and high risk treatment phases for VTE is important and can lead to a better outcome and quality of life for these children. We conducted this prospective study on symptomatic VTE in children with ALL to characterize the prevalence, the clinical characteristics, and potential clinical predictive factors for symptomatic VTE and the impact of thrombosis on treatment delays. Methods All patients (n=1083), age 1-18 years, diagnosed with B-cell precursor or T-cell ALL between June 2008 and July 2013 and enrolled in the NOPHO ALL 2008 treatment protocol in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden), Estonia or Lithuania were included in the study. Thrombotic events (TE) were prospectively recorded until the end of December 2013. TE was defined as objectively confirmed symptomatic TE. Main questions were: time of VTE occurrence, impact on treatment delay, type of CVL, dysfunction of the CVL, blood samples including D-dimers and thrombophilia screening, family history of TE, type and duration of antithrombotic therapy, and major bleeding during anticoagulation. Results The cumulative risk of symptomatic VTE was 6.0% (CI 95% 4.7-7.7) for children treated with the NOPHO- ALL 2008 protocol. No arterial TE was found. VTE occurred in median 80 (IQR 43-118) days in the SR and 104 (IQR 39-127) days in the IR protocol and were in majority of cases associated with asparaginase treatment (84.5%, 49/58). See figure 1 for the localization of the VTE. VTE had a high impact on the treatment in the patients. Treatment with asparaginase was shortened in half of patients with VTE and chemotherapy treatment delayed in 25%. Age ≥ 15 years and residual disease ≥ 5% after induction therapy was significantly associated with VTE in the multivariate analysis (Table 1). Conclusions Our findings indicate that Venous Thromboembolism (VTE): - is a major complication of ALL treatment - may lead to reduced intensity of the ALL treatment and subsequently possible long term impact on the EFS - risk is dependent on the patients age and residual disease after leukemia induction The possibility of identifying patients with elevated risk of VTE needs to be studied further and thromboprophylaxis for such patients during high-risk treatment phases can be considered in future ALL protocols. Table 1. Multivariate Cox regression analysis of the risk for VTE Factor HR (95% CI) P value Age category, years 1-7 8-14 15-17 Ref1.9 (1.0-3.7)6.2 (3.4-11.3) <0.000 0.044 0.000 Gender Male 1.6 (0.9-2.8) 0.074 ALL phenotype B-precursor T-cell Bilineage Ref2.3 (1.2-4.2)4.2 (1.0-17.4) 0.019 0.010 0.047 Residual disease ≥ 5% day 29 4.1 (1.9-9.0) 0.001 Figure 1. Localization of VTE Figure 1. Localization of VTE Disclosures No relevant conflicts of interest to declare." @default.
• W2213790147 created "2016-06-24" @default.
• W2213790147 creator A5005257038 @default.
• W2213790147 creator A5007917870 @default.
• W2213790147 creator A5015429380 @default.
• W2213790147 creator A5017612762 @default.
• W2213790147 creator A5032784001 @default.
• W2213790147 creator A5035541059 @default.
• W2213790147 creator A5036313684 @default.
• W2213790147 creator A5042089919 @default.
• W2213790147 creator A5054376745 @default.
• W2213790147 creator A5066819308 @default.
• W2213790147 creator A5071720008 @default.
• W2213790147 creator A5082921164 @default.
• W2213790147 creator A5084026968 @default.
• W2213790147 creator A5085002313 @default.
• W2213790147 creator A5087490874 @default.
• W2213790147 date "2014-12-06" @default.
• W2213790147 modified "2023-10-14" @default.
• W2213790147 title "Venous Thromboembolism in Children with Acute Lymphoblastic Leukemia in Northern Europe" @default.
• W2213790147 doi "https://doi.org/10.1182/blood.v124.21.3652.3652" @default.
• W2213790147 hasPublicationYear "2014" @default.
• W2213790147 type Work @default.
• W2213790147 sameAs 2213790147 @default.
• W2213790147 citedByCount "0" @default.
• W2213790147 crossrefType "journal-article" @default.
• W2213790147 hasAuthorship W2213790147A5005257038 @default.
• W2213790147 hasAuthorship W2213790147A5007917870 @default.
• W2213790147 hasAuthorship W2213790147A5015429380 @default.
• W2213790147 hasAuthorship W2213790147A5017612762 @default.
• W2213790147 hasAuthorship W2213790147A5032784001 @default.
• W2213790147 hasAuthorship W2213790147A5035541059 @default.
• W2213790147 hasAuthorship W2213790147A5036313684 @default.
• W2213790147 hasAuthorship W2213790147A5042089919 @default.
• W2213790147 hasAuthorship W2213790147A5054376745 @default.
• W2213790147 hasAuthorship W2213790147A5066819308 @default.
• W2213790147 hasAuthorship W2213790147A5071720008 @default.
• W2213790147 hasAuthorship W2213790147A5082921164 @default.
• W2213790147 hasAuthorship W2213790147A5084026968 @default.
• W2213790147 hasAuthorship W2213790147A5085002313 @default.
• W2213790147 hasAuthorship W2213790147A5087490874 @default.
• W2213790147 hasConcept C126322002 @default.
• W2213790147 hasConcept C141071460 @default.
• W2213790147 hasConcept C187212893 @default.
• W2213790147 hasConcept C188816634 @default.
• W2213790147 hasConcept C2777015399 @default.
• W2213790147 hasConcept C2778461978 @default.
• W2213790147 hasConcept C2778904437 @default.
• W2213790147 hasConcept C2780011451 @default.
• W2213790147 hasConcept C2780842393 @default.
• W2213790147 hasConcept C2780868729 @default.
• W2213790147 hasConcept C2781179581 @default.
• W2213790147 hasConcept C2909962599 @default.
• W2213790147 hasConcept C71924100 @default.
• W2213790147 hasConceptScore W2213790147C126322002 @default.
• W2213790147 hasConceptScore W2213790147C141071460 @default.
• W2213790147 hasConceptScore W2213790147C187212893 @default.
• W2213790147 hasConceptScore W2213790147C188816634 @default.
• W2213790147 hasConceptScore W2213790147C2777015399 @default.
• W2213790147 hasConceptScore W2213790147C2778461978 @default.
• W2213790147 hasConceptScore W2213790147C2778904437 @default.
• W2213790147 hasConceptScore W2213790147C2780011451 @default.
• W2213790147 hasConceptScore W2213790147C2780842393 @default.
• W2213790147 hasConceptScore W2213790147C2780868729 @default.
• W2213790147 hasConceptScore W2213790147C2781179581 @default.
• W2213790147 hasConceptScore W2213790147C2909962599 @default.
• W2213790147 hasConceptScore W2213790147C71924100 @default.
• W2213790147 hasLocation W22137901471 @default.
• W2213790147 hasOpenAccess W2213790147 @default.
• W2213790147 hasPrimaryLocation W22137901471 @default.
• W2213790147 isParatext "false" @default.
• W2213790147 isRetracted "false" @default.
• W2213790147 magId "2213790147" @default.
• W2213790147 workType "article" @default.